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Background: Intimate partner violence (IPV) can result in significant harm to women and families and is especially
prevalent when women are pregnant or recent mothers. Maternal and child health nurses (MCHN) in Victoria,
Australia are community-based nurse/midwives who see over 95% of all mothers with newborns. MCHN are in an
ideal position to identify and support women experiencing IPV, or refer them to specialist family violence services.
Evidence for IPV screening in primary health care is inconclusive to date. The Victorian government recently
required nurses to screen all mothers when babies are four weeks old, offering an opportunity to examine the
effectiveness of MCHN IPV screening practices. This protocol describes the development and design of MOVE, a
study to examine IPV screening effectiveness and the sustainability of screening practice.
Methods/design: MOVE is a cluster randomised trial of a good practice model of MCHN IPV screening involving
eight maternal and child health nurse teams in Melbourne, Victoria. Normalisation Process Theory (NPT) was
incorporated into the design, implementation and evaluation of the MOVE trial to enhance and evaluate
sustainability. Using NPT, the development stage combined participatory action research with intervention nurse
teams and a systematic review of nurse IPV studies to develop an intervention model incorporating consensus
guidelines, clinical pathway and strategies for individual nurses, their teams and family violence services. Following
twelve months’ implementation, primary outcomes assessed include IPV inquiry, IPV disclosure by women and
referral using data from MCHN routine data collection and a survey to all women giving birth in the previous eight
months. IPV will be measured using the Composite Abuse Scale. Process and impact evaluation data (online surveys
and key stakeholders interviews) will highlight NPT concepts to enhance sustainability of IPV identification and
referral. Data will be collected again in two years.
Discussion: MOVE will be the first randomised trial to determine IPV screening effectiveness in a community based
nurse setting and the first to examine sustainability of an IPV screening intervention. It will further inform the
debate about the effectiveness of IPV screening and describe IPV prevalence in a community based post-partum
and early infant population.
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Intimate partner violence (IPV) has been defined as any
behaviour by an intimate partner which causes physical,
sexual or psychological harm and IPV results in lasting
health damage particularly for women and children [1].
Pregnant women and those with infants are especially
vulnerable to IPV [2,3]. During pregnancy, IPV has been
estimated at between four to eight percent. It can com-
mence, continue or escalate in pregnancy and continue
into the postpartum period [4] with serious physical and
emotional consequences [5,6].
This study is located in Melbourne Australia, where
IPV among women in the childbearing years is estimated
to be the major contributor to the burden of illness
(especially to mental health issues) amongst women of
childbearing age. It is also a significant cause of adverse
pregnancy outcomes [7-9]. IPV has a significant impact
on women's parenting abilities, ultimately compromising
their children's development [9]. Current research indi-
cates that many children witnessing IPV can experience
behavioural, emotional, developmental and psychobio-
logical problems and difficulties with social competence
in the longer term [10]. The damage can be incremental,
but is also cumulative and while some children demon-
strate resiliency, it is not yet clear why. Therapeutic ser-
vices for mothers and their children who have
experienced violence are now developing and offer valu-
able sources of referral if the problem is detected early
and referrals made.
The potential for health services to support women
and children experiencing IPV in the early infant years
has been recognised with increasing government policies
around screening for IPV in the perinatal periods [11].
However, the evidence of benefit for women and chil-
dren of screening for IPV is scarce [12-14]. Nevertheless,
in spite of this lack of evidence, screening all women is a
common policy initiative and primary health care profes-
sionals are increasingly mandated to screen for IPV, es-
pecially in the childbearing years.
Health care professionals are commonly reluctant to
ask about IPV and women may also be reluctant to dis-
close. Common barriers for health-care professionals’
inquiry have been found to be lack of professional train-
ing, support, resources and workload [15]. While there
is evidence that training can increase clinician confi-
dence, rates of identification and referral in a given study
period, a major problem is the lack of evidence of the
sustainability of health-care provider behaviour change
and evidence for subsequent effective interventions [14].
This paper reports the protocol for an IPV screening
randomised trial located in maternal and child health
nurse clinics in Melbourne, Australia with an evaluation
of the elements contributing to sustained screening
practice.Screening for intimate partner violence (IPV)
IPV screening in health care systems can be defined as
routine and systematic inquiry of all presenting women
about their experience of intimate partner violence,
using a consistent set of questions [16]. It remains a
controversial subject as reviewers of the same evidence
have come to different conclusions about its effective-
ness, and as to whether it should be recommended
[14,16-18]. Scholars have identified many barriers to uni-
versal IPV screening, including health care provider atti-
tudes, heavy workloads, and lack of recurrent training,
of adequate referral services and other resourcing sup-
port, and the presence of partners during consultations
[14,19-22]. Nevertheless, governments are increasingly
turning to universal screening as a policy option with
varying levels of readiness to address the identified bar-
riers to sustaining screening practices. There have been
varying rates of screening coverage reported, depending
on whether screening data are collected routinely or
‘snapshots’ are taken when service providers know their
governments are scrutinizing performance at a particular
time [16]. While routine screening is commonly
assumed to be a desirable goal, a recent trial of an alter-
native approach, system supported ‘case finding’ or
inquiry when IPV symptoms are present by primary care
providers, was successful in raising identification and re-
ferral numbers, although benefits for women are un-
known [23].
The Victorian maternal and child health service and the
context for IPCV screening
Victorian maternal and child health nurses (MCHNs)
are trained nurse midwives who visit over 95% of all
Victorian mothers with newborns at home and con-
tinue to offer support at their local centres until the
children are six years old [24]. This free, universal,
comprehensive primary health-care service aims to pro-
vide health promotion, illness prevention, early detec-
tion of developmental problems, and intervention to
enhance the health and wellbeing of young children
and their families. Australia has three tiers of govern-
ment: federal or national; state (or territory) and local
government or council. MCHN nursing is located and
managed in the complex local government environ-
ment, while implementing policies formulated at state
government level. They are often funded at local gov-
ernment level (usually 60% local government and 40%
state government).
In late 2009, just as this proposed trial of IPV screen-
ing versus usual care was funded, a new comprehensive
approach to screening children and their mothers for
other common problems and developmental delays, Key
Ages and Stages (KAS), was introduced into Victorian
maternal and child health nursing practice [25]. Under
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required to screen all mothers for family violence - the
government’s preferred term, which includes child abuse
(not only IPV) - when their babies are four weeks old.
MCHNs were provided with three hours training to
use a Common Risk Assessment Framework, offering
a common definition of IPV for health care provi-
ders, police, family violence services and courts,
symptoms to look for and referral processes. Included in
KAS strategies were computer prompts for the now
mandated four week IPV screening, any screening at
a later consultation, and the requirement to report
regular data about IPV screening, safety plans and
referrals and other child health screening and referral
rates to government.
Nurses are required to ask the following questions
about family violence:
1. Are you in any way worried about the safety of
yourself or your children?
2. Are you afraid of someone in your family?
3. Has anyone in your household ever pushed, hit,
kicked, punched or otherwise hurt you?
4. Would you like help with this now?
MOSAIC (MOtherS' advocates in the community)
Prior to this government initiative, in our previous IPV
trial of non-professional mother-to-mother support for
pregnant or recent abused mothers, known as MOSAIC
[26], MCH nurses struggled to identify and refer clients
experiencing violence despite comprehensive six-hour
training by a domestic violence training agency and add-
itional resources (referral booklets, posters etc.). An im-
pact evaluation conducted at the end of the study,
showed that 66% of nurses said that they were comfort-
able or very comfortable asking about partner violence,
while 18% remained uncomfortable. Thirty-five percent
cited partners or family members being present as the
major obstacle to asking about IPV, followed by fear
of embarrassing women (14%) and the need to focus
on the child as their priority (13%). When asked what
made it difficult, 42% of nurses said women's reluc-
tance to take further steps, referral agencies’ waiting
lists (22%) and the difficulty of finding support for
women with special needs (17%). When asked what
should be put in place to assist other nurses to de-
velop their skills and increase their confidence in this
area, nurses suggested regular training (1); MCHN
specific clinical guidelines for IPV (2); and an MCHN
clinical pathway (3).
Following on from MCHN feedback in MOSAIC, this
study originally aimed to compare implementation of
IPV screening with usual care; however with the intro-
duction of mandatory IPV screening of all recentmothers when babies are four weeks old, the trial design
was modified to evaluate an enhanced model of IPV
screening addressing some of the identified challenges
for nurses and addressing the issue of sustainability,
compared with basic mandatory IPV screening.
Trial registration
This trial was registered with the Australian and New
Zealand Clinical Trials Registry (ACTRN12609000424202).
Ethics
This study was approved by the Human Ethics Com-
mittee, La Trobe University (UHEC 08–142) and also
by the University of Melbourne and the Victorian Govern-
ment Department of Education and Early Childhood
Development.
Aims
1) To compare whether, after implementing an
evidence-based consensus model of good IPV
practice for twelve months, MCH nurses in the
intervention arm more frequently than nurses in the
comparison arm Ask about IPV among their client population
 Refer women experiencing IPV to services
 Inquire about the safety of women and children in
the relationship
2) More women attending MCH centres in the
intervention arm than in the comparison arm:
 Are asked about IPV
 Disclose/discuss any abuse and
 Are satisfied with the quality of care and support
they receive
3) To provide an accurate estimate of the proportion of
MCH clients who have ever or who are currently
experiencing IPV and those abused when pregnant
The primary outcomes for the study are to
1. Increase the proportion of women (15%) reporting
that they have been asked about family violence or
nurses reporting they have screened for family
violence (i.e. questions from the Key Ages and
Stages protocol)
2. Increase the proportion of women disclosing IPV
(discussing IPV with MCH nurse) or nurses
reporting discussing safety plans
3. Increase the proportion of referrals reported by
nurses or women reporting being offered referrals
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1. Estimate the prevalence of any IPV in the previous
12 months (measured with the Composite Abuse
Scale, ≥3-6, and ≥7), IPV during pregnancy and any
reported child abuse
2. Increase the proportion of MCH clients reporting
satisfaction with quality of care and support they
receive for themselves, their partners and their
children
3. Investigate the proportions of women reporting any
harm arising from (a) responding to questions about
IPV in their MCHN consultation or (b) responding
to questions about IPV in the survey)Design
MOVE is a cluster randomised trial. It is located in
MCHN teams in the north-west suburbs of Melbourne,
consisting of 80 nursing centres and over 160 nurses
(Figure 1).Recruitment of clusters: MCH nurse teams in north west
Melbourne
Team leaders of eight MCH teams, located in eight local
government areas were invited to participate in a previ-
ous study MOSAIC [26] and all agreed. Each team
leader and their manager signed a supplementary letter
to the original Memorandum of Understanding to par-
ticipate in this subsequent study.MOVE proc
Intervention 
Nurse 
consultant 
input (PAR)
Systematic 
review
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Figure 1 MOVE processes.Randomization
The randomization of nurse teams at that time occurred
at a public randomization meeting. Names of the
MCHN teams, stratified by numbers of births per local
government area and paired in size, were concealed in
opaque envelopes and the random selection made by an
invited guest from outside the project or research team.
MCH Team Leaders were present to ensure the fairness
of the process and to check the contents of the envel-
opes prior to their being sealed. For MOVE, all eight
teams agreed to the reverse of the previous randomisa-
tion allocation, so that teams allocated to comparison
status in MOSAIC formed the intervention arm for
MOVE and those previously allocated intervention sta-
tus formed the comparison arm.Blinding (allocation concealment)
Given the nature of the intervention, it has not been
possible to blind MCHN teams or nurses to their status.
The Project Coordinator is not blind to MCHN team
participant status either, as she is required to liaise with
intervention team MCHN consultants. Women attend-
ing the MCHN service are blind to their status as
randomization is by cluster and consent to participate in
the trial was given at MCH team level.Blinding (outcome assessment)
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instruments on line using an anonymised format and
data are stored in a secure database
(b) MCHN complete anonymised routine computer-
ized screen data that are summarized annually and for-
warded to the Department of Education and Early
Childhood Development
(c) Names and addresses of women attending MCH
clinics are not accessible to research staff because of
privacy regulations. Surveys are sent to women in anon-
ymised questionnaire booklets mailed to their home by a
local government agency with an accompanying letter
from their MCHN team leader. Outcomes were pre-
specified at the time of our trial registration. Analyses
are to be carried out by the study statistician blinded for
trial arm following data entry of women’s survey
responses by an independent data company.
Survey sample size calculation
(b) We calculated that around 8-10% of women attend-
ing each of the eight MCH services will have been
abused in the previous 12 months [4]. Following twelve
months implementation, we will send a mailed question-
naire to all women who have given birth in the previous
8 months in both the comparison and intervention mu-
nicipalities (5000 per arm). This sample size enables us
to detect a predicted increase of 15% average disclosure
found previously in a screening intervention of screening
vs usual care [27]. We have taken into account both the
numbers of births in participating local government
areas (using most recent published data (2005), the likely
response fraction (55-65% following mailed surveys and
a reminder postcard - a modified Dillman procedure)
and also adjusted for clustering. We adjusted for an
intra-cluster correlation of 0.02 from a previous IPV pri-
mary care study [28].
Outcome measures
Routine data
Data reported routinely to the Victorian government is
entered at the time of consultation by the MCH nurse.
In relation to IPV screening, these data include:
 Whether the nurse reports asking about any of three
family violence questions to which the answer is
yes/no and at what time point: home visit; four
weeks, eight weeks, four, eight, twelve or eighteen
months.
 Whether the nurse reports making a safety plan
 Whether the nurse reports making a referral
We will compare rates of inquiry, safety plans and
referrals between intervention and comparison arms at
four weeks, four months and twelve months.Survey measures
The survey booklet ‘Women’s Experiences of Health
Care and Support with a New Baby’ has seven sections:
(A) About your baby; (B) About your own health follow-
ing your baby; (C) Your health care support; (D) Other
care and support you receive; (E) Relationships and fam-
ily; (F) You and your partner; (G) About you. It is
designed to maximize women’s safety as it is mailed to
her home. Section F includes questions about intimate
partner violence measured using Hegarty’s Composite
Abuse Scale [29], together with questions about being
asked, disclosure (and comfort to disclose), rates of re-
ferral and satisfaction measures for herself, her children
and in relation to strategies for her partner.
The questionnaire also includes depression and anx-
iety measures using the DASS-21 [30,31]; women’s
experiences of motherhood measured with the Experi-
ence of Motherhood Scale [32] and a range of other
assessments of women’s experiences.
Checklists
These data will only be available in the intervention arm,
as they are a screening intervention tool (see below).
Nurses use these screening self-completion forms with
women and retain these for collection by MOVE re-
search staff. They also record the screening consultation
time (three or four months or later) and these will be
analysed especially for the three month screening point,
when routine data are not recorded.
Methods
Theoretical framework
An overarching goal of this study is the development of
a sustainable model of MCHN good practice in identifi-
cation, support and referral of women experiencing IPV.
There has been considerable debate about the limita-
tions of programs aimed at enhancing health care pro-
fessional behavior change [33]. Further, it is now
recognized that when interventions themselves are com-
plex (such as the introduction of primary care nurse IPV
screening) and operate in a complex environment (such
as both state and local government arenas) that atten-
tion to theory, process and in particular, context are
required if they are to be successfully integrated into
routine practice [34]. This requires greater attention to
the development, testing and refinement of an interven-
tion before effectiveness testing.
May et al’s Normalization Process Theory [35-37] pro-
poses four domains of work which require particular at-
tention in the design, development, implementation and
evaluation cycle of health system and health professional
behavior change. We outline in brief how, in relation to
the work of MCHN, we interpreted the core NPT con-
cepts in relation to MCH nurse work and incorporated
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mentation, and process and impact evaluation of this
trial. In terms of the core concepts, we interpreted them
as related to MCH nursing work as follows:
 Coherence (how MCH nurses interpret, accept and
value their role in, and the concept of IPV
screening)
 Cognitive participation (how MCH nurses engage
with the work: who introduces, leads, maintains and
participates in IPV screening) Collective Action – involves four components:
∘ Interactional workability – how and when IPV
screening is conducted, how screening roles are
organized within teams, resources improving
nurse/client screening interaction, who is
allocated to the work
∘ Relational integration (accountability, knowledge
and trust in IPV screening working relationships
including team functioning and including nurse
safety)
∘ Skill set workability (do MCH nurses think they
have the required skills, resources and rewards
to conduct IPV screening effectively)
∘ Contextual integration (how well is screening
organized, funded and supported in their
working context of local and state government) Reflexive monitoring ( how do MCH nurses and
teams know how effective or well their IPV
screening is going)
Intervention development phase – toward a model of
sustainable good practice
This phase involved three strategies:
1. We conducted Participatory Action Research (PAR)
with four volunteer MCHN consultants (one from
each of four intervention MCHN teams) who
explored the barriers and sought answers to these
problems within their teams. PAR has been defined
as ‘collective, self reflective inquiry that researchers
and participants undertake, so they can understand
and improve upon the practices in which they
participate and the situations in which they find
themselves’ [38]. Over a six-month period, at regular
monthly meetings with MOVE staff, questions
derived from earlier feedback in MOSAIC [26],
discussion about barriers and enablers of IPV
screening practices, and informed by the NPT
framework [36] were agreed and nurse consultants
took them away to their teams for discussion andfeedback. The two groups (nurse consultants and
MOVE staff ) met over a six month period to discuss
team feedback and reach agreement on the major
aspects of a good practice model to be outlined in
clinical pathways and guidelines. All meetings were
recorded on tape and notes derived from them
informed further discussion. We also drew on a GP
systems intervention then being piloted in the UK
(IRIS [23]) for strategies to strengthen links between
clinicians and family violence services.
2. A systematic review of interventions (with controlled
or comparison designs), guidelines or protocols
targeted at improving the response of health care
practitioners (HCPs) working with women
experiencing IPV, their children and partners using
abusive behaviors was conducted using Medline,
Cochrane and Campbell Collaboration databases and
CINAHL. Further details of the search terms and
inclusion/exclusion criteria are available from the
authors. Results were synthesized and presented to
the nurse consultant and research group and the
advisory group of key stakeholders.
3. Using a method we have previously used in an
international collaboration to develop GP guidelines
[39], we facilitated multidisciplinary group
discussions between the nurse consultants and study
reference group to independently score and then
reach agreement about the content and format of the
guidelines, clinical pathway and maternal health
checklist – a woman’s self-completion screening tool
(all available at http://www.latrobe.edu.au/mchr/
html/move.html ). A penultimate draft of these
materials was presented and finalized at a reference
group meeting and further detail of the model’s key
elements are presented below.
Screening time
The move intervention model
MCH nurses expressed concern about an early screening
time (e.g. home visit or four weeks) for the following
reasons: (a) women were still recovering from the birth
and focused their attention on the baby’s not their own
needs; (b) nurses had had insufficient time to establish a
trusting relationship with the woman which would make
it easier to ask a sensitive question and enable disclosure
(c) >30% of Victorian women have had Caesarean sec-
tion and advised not to drive for six weeks, so are fre-
quently accompanied by someone, making it sometimes
challenging to ensure screening safely. Nurses therefore
suggested that the optimum screening time would be at
a three or four month visit when women could be
advised ahead of time that the visit would be focused on
their needs and that they would be completing a
women’s health checklist. They also suggested that they
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and told accompanying partners that the questions would
include discussion of menstruation and breast problems,
and that partners may not want to be present. Two teams
created an additional woman-focused three month visit,
and the other two teams added fifteen minutes to the four
month KAS-funded visit to be focused on maternal needs.
Maternal health checklist
Evidence from the systematic review suggested that
women preferred self-completion screening methods (e.g.
paper or computer based) rather than face-to-face screen-
ing inquiry (ref ). The maternal health checklist was
developed as a tear-off pad consisting of an A-5 set
of questions for women to self-complete at the agreed
consultation which focused on maternal health, rather
than the development of the baby, who is the MCH
nurses’ primary client. When women arrived at this visit,
they were given the checklist and asked to complete it in a
quiet corner and let the nurse know when finished. The
checklist consists of a set of questions about maternal
health, beginning with questions about physical health,
such as headache, nipple or bowel problems then moving
to those about depression, contraception or drug misuse
to the same family violence questions being asked as part
of the Key Ages and Stages (KAS) mandatory screen-
ing at four weeks. After discussion, MOVE added two
further questions to this list. Just before the KAS ques-
tions, we added:
Do you have any problems in your relationships or in-
timacy with your partner? and Has anyone in your
household ever humiliated you or tried to control what
you can or cannot do? The first question was seen as
useful for women who may want to discuss non-specific
problems in the relationship prior to disclosure and the
latter because it is central to intimate partner abusive
behavior. If a woman ticked any of the relationship or
any family violence questions, nurses were asked to initi-
ate a discussion about these in ways that felt appropriate
and comfortable. The completed checklist form is
retained as part of the study data collection.
Clinical guidelines and pathway
The eight-page guidelines were designed so that the clin-
ical pathway was on the front page and summarized
recommended actions and also feature principles of
good practice along the bottom.
These principles are:
 SEEK SUPPORT Consult your team leader, nurse
mentor, family violence liaison worker.
 MAINTAIN PRIVACY & CONFIDENTIALITY
 SAFETY FIRST of nurse, women & children
 BE NON JUDGEMENTAL MAINTAIN PROFESSIONAL BOUNDARIES your
role is to listen, support & refer
 MINDFULNESS Stages of change. Where is the
woman up to?
Further inside are four sections entitled:
 Inquire and Connect (this section deals with
processes for screening including cross-cultural
practice and nurse safety – a nursing concern)
 Assess and Support (this section deals with the
processes following disclosure and includes a
section aiming to alert the nurse to the fact that
not all women are ready either to disclose or to
accept referrals. The section stresses asking about
women’s circumstances, supportive listening and
was developed with the knowledge that some
nurses had difficulty with accepting women’s
decision not to leave when they were unready. It
also outlines ‘warm referrals’ and gives advice
about clinical decision-making when children are
at risk
 Document (together with the Women’s Legal
Resource Service, MOVE developed a guide to
objective documentation which would be useful for
court purposes should a nurse be required to give
evidence in court)
 Quality Assurance and Routine Practice (this
section includes routine team monitoring, support
for nurses experiencing family violence and mindful
practice.
Each section outlines the Aims, Guidelines and Imple-
mentation issues, and details practice, including which
type of nurse – the universal nurse, the nurse mentor or
coordinator/team leader – has responsibility for ensur-
ing implementation.
Nurse mentors
Nurse mentors volunteer or were chosen by team lea-
ders as those nurses with a special interest in and/or
skills in family violence practice. They provide support
to individual nurses in the team struggling with difficult
cases or wanting to practice their IPV inquiry skills.
They act as a ‘practice champion’ in the team.
The role of these nurses includes:
 Liaising with the family violence liaison officers in
community-based family violence services
 Accompanying MCHNs who are undertaking a
home visit for additional safety where there is or is
likely to be IPV
 Facilitating and maintaining discussions within the
team about IPV issues
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support person for nurses managing difficult cases
of IPV
Family violence MCHN liaison workers
MOVE adopted the model outlined in the IRIS study
[20] of a family violence agency staff member who has a
special responsibility for liaison with primary care ser-
vices; in this case, with the MCH nurse teams to
strengthen links and referral options. These staff are
funded, employed and managed by the family violence
services, with agreed responsibility during the trial for:
 Attending MCHN team meetings to familiarize the
team with the FV service and other relevant
community-based services, e.g. community police
 Facilitating referrals and secondary referrals to
family violence services
 Providing feedback about referrals, debriefing if
necessary
 Participating in evaluation interviews
The geographical location of the two family violence
services resulted in one family violence liaison worker li-
aising with one team and the other liaising with three
teams.
Implementation
Following all stakeholders’ agreement with the new
model, nursing consultants and MOVE staff briefed the
intervention teams and provided them all with newly
developed resources (http://www.latrobe.edu.au/mchr/
html/move.html) including a guide to IPV documenta-
tion. Teams undertook to implement the MOVE model
over a twelve month period. During the intervention
period, MOVE research staff remained at a distance to
enhance sustainability, and reliance on research staff was
kept to a minimum.
Data collection
Process evaluation: Online survey questions for nurses,
structured using tenets of the Normalization Process
Theory [36] were developed in consultation with nurse
consultants, face validity was checked with assessment
by stakeholders in the reference group and they were
then piloted with an MCH nurse team outside the trial
to ensure acceptability, relevance and timeliness.
The online survey was developed for use six months
into the implementation year with all participating
nurses in both arms to elicit MCHN current IPV screen-
ing knowledge, attitudes and work practices.
At the same time, telephone or face-to-face interviews
were planned with MCH nurse mentors, team leaders,
family violence liaison officers and supervising staff fromfamily violence agencies to elicit factors related to key
concepts of the NPT framework. Interviews were con-
ducted by external staff.
Impact evaluation - online survey data
Three months after the end of the intervention, a second
anonymous online survey of MCH nurses in both arms
of the study (~160) was developed to assess their levels
of confidence about and attitudes to IPV screening, per-
ceived rates of inquiry about women’s and children’s
safety, referral to family violence agencies for all family
members, team functioning and support for IPV screen-
ing and perceptions of their own safety. The surveys and
interviews will be repeated two years after the end of the
intervention to assess sustainability of the screening pro-
cesses. Interviews conducted by external staff with key
stakeholders will also be conducted at the end of the
intervention and two years later.
Outcome evaluation - primary and secondary outcomes
Routine data With local government permission, we
will retrieve routine data about family violence described
above for the intervention period for all nurses in both
arms of the study. We will seek to retrieve it again in
2013, two years post intervention.
Women’s survey questionnaire We have developed a
questionnaire survey to be sent to 10,000 women (5000
in either arm) who have given birth over an eight month
period. This sample gives us power to detect differences
in the primary outcome. Included are all the primary
and secondary outcome measures and a valid and reli-
able measure of intimate partner violence (Composite
Abuse Scale) [29].
The data management company employed to manage
the survey data has been subcontracted to the local gov-
ernment councils who have given the company staff ac-
cess to women client’s addresses. They will mail the
surveys and two rounds of reminder cards. Surveys will
be returned to the company for electronic data entry
and double-coding.
Checklists (http://www.latrobe.edu.au/mchr/html/move.
html) MOVE staff will retrieve all checklists retained by
intervention nurses at intervention midpoint (six
months) and after the implementation period has fin-
ished. Data will be checked for completion of screen and
screening period.
Data analysis and reporting
Women’s survey
The MCH consumer survey data will be cleaned,
double-coded and entered into a secure database by an
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be forwarded to a statistician blinded to study arm.
Women’s characteristics for socio-demographic and
birth characteristics will be compared by trial arm to en-
sure that randomization was effective. The representa-
tiveness of the women responding to the survey (i.e.
sample bias due to differential study participation rates)
will be assessed by comparison with routine perinatal
data for all women giving birth in the region for the
comparison year (Victorian Perinatal Data Collection
Unit, DHS).
All data will be analyzed by intention-to-treat and vari-
ance estimates in models will be adjusted for the effect
of the clustered (LGA) selection of participants. We will
analyze data using contingency table analyses for bivari-
ate and binary logistic regression with robust standard
errors for multivariate models. For primary outcomes,
we will analyze data stratified by and adjusted for
women’s abuse status and for potentially significant con-
founding variables (where randomization is less effective
in removing bias across study groups), including
women’s socio-economic status.
For MOVE primary outcomes, we will report:
 Any difference in proportions by trial arm (from
survey and routine data) of screening for IPV
(questions about fear of a partner; physical abuse
and concern about the safety of their children) will
be reported separately and as a screening inquiry
composite variable
 Any difference in proportions by trial arm of women
reporting IPV (Composite Abuse Scale ≥ 3 and ≥7)
who have discussed IPV with their MCH nurse
 Any difference in proportions by trial arm of nurses
who have reported that they have made safety plans
with women clients
 Any difference in proportions by trial arm of women
reporting IPV (Composite Abuse Scale ≥ 3 and ≥7)
who have been offered a referral (if sufficient
numbers) or nurses who report they have made
referrals for IPV (routine data)
The following measures will be reported for the overall
population and also by trial arm.
 Any difference in proportions by trial arm of abused
and non-abused women reporting satisfaction with
their MCH nursing care
 Intimate partner violence measured by the
Composite Abuse Scale reported for women with
scores ≥ 3 and those with scores≥ 7
 Proportions ever having been afraid and currently
afraid of their partner Proportions reporting partner abuse during
pregnancy for the recent pregnancy and any in a
past pregnancy.
 Proportions abused in pregnancy by family members
and by other known persons (e.g. employer,
housemate)
 Proportions physically, sexually, emotionally abused
or neglected as children
 Proportions reporting harm from IPV screening or
participating in an IPV screening study
Process and impact evaluation
Online survey data will be downloaded by MOVE staff
from the online survey database and entered into an
Excel spreadsheet. Responses will be grouped by MCHN
nurse team and separated into trial arms. Responses will
be counted and proportions of responses for each
questions calculated. These data will be compared across
trial arm and analyzed using bivariate chi-square tests
of independence or other non-parametric analytical
approaches where appropriate.
Qualitative data (interviews with key stakeholders) will
be transcribed verbatim, coded thematically exploring
NPT constructs and for any other significant patterns
and any outliers.
Dissemination and translation
We propose to present the findings from this study to
Victorian and Australian policymakers at relevant na-
tional conferences, in person to the Victorian Govern-
ment Department responsible for MCH nursing, at
international IPV and nursing conferences, in peer-
reviewed and professional journals.
Two year follow-up
We propose to seek permission to obtain routine data
for screening inquiry, safety plans and referrals for IPV
two years after the MOVE implementation completion.
We will also aim to conduct a survey with all nurses in
the two arms of the MOVE trial to investigate the sus-
tainability of the screening intervention, using NPT con-
structs. Analyses of these data will be conducted as
outlined above.
Discussion
MOVE will be the first randomised trial to determine
IPV screening effectiveness in a community based nurse
setting and the first to examine sustainability of an IPV
screening intervention. Screening for IPV remains a con-
troversial area, but governments especially in high and
middle income countries continue to implement screen-
ing policy in health care settings, without addressing the
key barriers reported by primary care professionals, es-
pecially workloads, ongoing training and lack of effective
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barriers, there is doubt about the sustainability or effect-
iveness of screening [27]. Normalisation Process Theory
[36] has been developed to support sustainability of im-
plementation and evaluation of complex interventions
and complex settings and is appropriate to the effective-
ness and sustainability questions addressed by the
MOVE trial.
This study is being conducted in Victoria, Australia
where legal sanctions and strong family violence policies
exist at national and state level. As a high income coun-
try crisis and outreach responses for women are funded
and supported (although stretched to meet need),
improved policing responses and intervention/protection
orders available from magistrates courts tailored to fam-
ily violence victims are also available. There are also be-
haviour change groups for male perpetrators and
services for children who have experienced family vio-
lence. In this context, when primary care providers iden-
tify women experiencing family violence, services exist
to support women and sanctions are available (however
limited) to prevent further harm. As a result of previous
training conducted in the MOSAIC study and the fur-
ther training offered in the new Victorian Key Ages and
Stages initiative, MOVE nurse teams in both arms of this
study have been well trained to screen and refer women
experiencing violence. Of all Victorian MCH nurses,
nurses in this study are well prepared and the interven-
tion arm nurses even better prepared, following their ac-
tive involvement in developing a good practice model.
MOVE results will further inform the debate about the
effectiveness of IPV screening and describe IPV preva-
lence in a community based post-partum and early in-
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